Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 31, 2023 08:00 ET | Source: AltruBio Inc.

AltruBio to Present at the 2023 BIO International Convention

SAN FRANCISCO, May 31, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
May 08, 2023 08:00 ET | Source: AltruBio Inc.

AltruBio Announces Poster Presentation at Digestive Disease Week Conference 2023

SAN FRANCISCO, May 08, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
March 09, 2023 08:00 ET | Source: AltruBio Inc.

AltruBio Announces Panels and Presentations at Three March Healthcare Conferences

SAN FRANCISCO, March 09, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment...
January 23, 2023 09:00 ET | Source: AltruBio Inc.

AltruBio Announces First Patient Dosed in Phase 1 Trial of Next-Generation Immune Checkpoint Enhancer ALTB-268 for the Treatment of Ulcerative Colitis

SAN FRANCISCO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
January 19, 2023 11:00 ET | Source: AltruBio Inc.

AltruBio Announces Poster Presentation on Immune Checkpoint Enhancer, ALTB-168 at Crohn’s & Colitis Congress 2023

SAN FRANCISCO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
January 05, 2023 08:00 ET | Source: AltruBio Inc.

AltruBio to Present at Biotech Showcase™ 2023

SAN FRANCISCO, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
December 10, 2022 10:00 ET | Source: AltruBio Inc.

AltruBio Presents New Positive Data from its Completed Phase 1b Study Evaluating ALTB-168 in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022

-Participants with SR-aGVHD disease achieved an ORR of 67% and CR of 17% as measured by best response- -Participants with TR-aGVHD (11 of 12 concomitant ruxolitinib) achieved an ORR of 67% and CR...
December 08, 2022 08:00 ET | Source: AltruBio Inc.

AltruBio Hosting Research & Development Update on Immune Checkpoint Enhancer Platform for T Cell Mediated Immunological Diseases

The Company will Provide an Overview of its Immune Checkpoint Enhancer (ICE) Platform Clinical Proof-of-Concept Data from its First Generation ICE, ALTB-168, will be Presented, Including Development...
December 06, 2022 08:00 ET | Source: AltruBio Inc.

AltruBio Announces FDA Clearance of IND Application for ALTB-268, a Next-Generation Immune Checkpoint Enhancer for the Treatment of Ulcerative Colitis

-Next-generation PSGL-1 agonist antibody with clinically proven mechanism of action receives IND clearance- -Phase 1 clinical trial expected to launch in 1H 2023 and will evaluate the safety,...
November 08, 2022 08:00 ET | Source: AltruBio Inc.

AltruBio to Present at Stifel 2022 Healthcare Conference

SAN FRANCISCO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...